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Primary	central	nervous	system	lymphoma	(PCNSL)	is	a	rare	subtype	of	lymphoma	
that	 arises	within	 the	brain	or	 the	eyes.	PCNSL	 recurs	within	 the	central	nervous	
system	(CNS)	in	most	relapsed	cases,	whereas	extra-	CNS	relapse	is	experienced	in	
rare	cases.	The	present	study	aimed	at	identifying	the	presence	of	common	precur-
sor	cells	(CPC)	for	primary	intra-	and	relapsed	extra-	CNS	tumors,	and	further	assess-
ing	the	initiating	events	in	bone	marrow	(BM).	Targeted	deep	sequencing	was	carried	
out	for	five	paired	primary	intra-	and	relapsed	extra-	CNS	tumors	of	PCNSL.	Two	to	
five	mutations	were	shared	by	each	pair	of	intra-	and	extra-	CNS	tumors.	In	particular,	
MYD88	 mutations,	 L265P	 in	 three	 and	 P258L	 in	 one,	 were	 shared	 by	 four	 pairs.	
Unique	somatic	mutations	were	observed	in	all	five	intra-	CNS	tumors	and	in	four	out	
of	 five	extra-	CNS	tumors.	Remarkably,	 IgH	 clones	 in	 the	 intra-	and	the	extra-	CNS	
tumors	in	two	pairs	were	distinct	from	each	other,	whereas	one	pair	of	tumors	shared	
identical	monoclonal	 IgH	 rearrangement.	 In	a	cohort	of	23	PCNSL	patients,	L265P	
MYD88	 mutations	 were	 examined	 in	 tumor-	free	 BM	mononuclear	 cells	 (MNC)	 in	
which	 the	PCNSL	 tumors	had	L265P	MYD88	mutations.	L265P	MYD88	mutations	
were	detected	by	a	droplet	digital	PCR	method	in	nine	out	of	23	bone	marrow	mono-
nuclear	 cells.	These	 results	 suggest	 that	 intra-	 and	extra-	tumors	are	derived	 from	
CPC	with	MYD88	mutations	in	most	PCNSL,	arising	either	before	or	after	IgH rear-
rangement.	The	initiating	MYD88	mutations	may	occur	during	B-	cell	differentiation	
in	BM.
K E Y W O R D S
bone	marrow,	common	precursor	cell,	IgH	rearrangement,	L265P	MYD88,	primary	central	
nervous	system	lymphoma
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1  | INTRODUC TION
Primary	central	nervous	system	lymphoma	(PCNSL)	is	a	rare	form	of	
diffuse	 large	B-	cell	 lymphoma	(DLBCL)	that	arises	within	the	brain	
or eyes.1	Recent	exome	sequencing	studies	have	shown	that	genes	
of	the	Toll-	like	receptor	and	B-	cell	receptor	signaling	pathways	are	
frequently	mutated	 in	PCNSL.2-4	Notably,	the	hotspot	mutation	of	
MYD88,	which	results	 in	 the	conversion	from	 leucine	to	proline	at	
the	265th	position	(L265P	MYD88	mutation),	has	a	very	high	preva-
lence	in	patients	with	PCNSL	(38%-	85.4%).2-5
A	 previous	 report	 showed	 that	 the	 L265P	 MYD88	 mutation,	
but	not	other	mutations,	 found	 in	PCNSL	 tumors	was	detected	 in	
peripheral	blood	mononuclear	cells	(PBMNC).3	This	may	imply	that	
the	L265P	MYD88	mutation	may	occur	at	the	extra-	central	nervous	
system	 (CNS)	 compartment	 as	 the	 initial	 genetic	 event	 for	PCNSL	
development.	However,	the	actual	developmental	process	of	PCNSL	
should	be	examined	from	a	different	point	of	view.
Comparisons	between	genomic	alterations	 in	 tumors	at	diag-
nosis	and	those	at	relapse	led	to	the	suggestion	of	common	pre-
cursor	 cells	 (CPC)	 for	 the	 primary	 and	 relapsed	 tumors	 in	 other	
types	of	 lymphoma	such	as	follicular	 lymphomas	(FL)	and	mantle	
cell	 lymphomas	 (MCL).6,7	Primary	and	relapsed	tumors	of	FL	and	
MCL	may	 arise	 through	 a	divergent	 evolution	pattern	 from	CPC	
by	acquiring	mutations	specific	 to	either	primary	or	 relapsed	tu-
mors.6,7	 PCNSL	 recurs	 within	 the	 CNS	 in	 most	 relapsed	 cases,	
whereas	 extra-	CNS	 relapse	 (systemic	 relapse)	 is	 experienced	 in	
<7%	of	the	relapsed	cases.1	The	present	study	aimed	at	identifying	
the	presence	of	CPC	with	multiple	mutations	by	examining	paired	
primary	intra-	and	relapsed	extra-	CNS	tumors	and	further	assess-
ing	 the	 initiating	events	by	examining	MYD88	mutations	 in	bone	
marrow	mononuclear	cells	(BMMNC).
2  | MATERIAL S AND METHODS
2.1 | Targeted deep sequencing by Ion Torrent PGM
Targeted	 deep	 sequencing	 (TDS)	 was	 carried	 out	 in	 five	 paired	
primary	 intra-	CNS	 and	 relapsed	 extra-	CNS	 tumors	 and	 BMMNC	
using	 the	 Lymphopanel	 for	34	 candidate	 genes8	 and	our	 in-	house	
PCNSL	panel	 for	12	candidate	genes1	 (Tables	S1	and	S2).	Because	
seven	genes	overlapped,	39	candidate	genes	were	analyzed	in	total.	
The	mutational	profiles	of	five	primary	intra-	CNS	tumors	by	our	in-	
house	PCNSL	panel	were	previously	described.1	Both	panels	were	
designed	 by	 custom	 Ampliseq	 Designer	 system	 (Thermo	 Fisher	
Scientific,	Waltham,	MA,	USA).	Libraries	were	prepared	 from	5	ng	
tumor	DNAs	using	the	Ion	AmpliSeq	Library	Kit	2.0	(Thermo	Fisher	
Scientific),	according	to	the	manufacturer’s	instructions.	Sequencing	
was	carried	out	using	Ion	318	chips	on	Ion	Torrent	Personal	Genome	
Machine	 (PGM)	 (Thermo	Fisher	Scientific).	Data	were	analyzed	by	
carrying	 out	 alignment	 with	 the	 hg19	 human	 reference	 genome	
and	variant	calling	was	done	with	Variant	Caller	5.2	(Thermo	Fisher	
Scientific).	 Single	 nucleotide	 variants	 or	 insertions/deletions	 with	
frequencies	 of	 3%	or	more	were	 considered	 candidate	mutations.	
These	mutations	were	validated	by	genomic	PCR	followed	by	Sanger	
sequencing.	The	primers	are	listed	in	Table	S3.
2.2 | Polymerase chain reaction detection of 
complementarity- determining region 3 region of Ig 
heavy chain genes
Polymerase	 chain	 reaction	 (PCR)	 for	 amplification	 of	 the	
complementarity-	determining	region	3	(CDR3)	was	carried	out	in	a	
semi-	nested	approach.9	The	first	step	of	PCR	was	carried	out	using	
primer	FR2A	or	FR3A	plus	a	reverse	primer	directed	at	the	joining	
region	(LJH).	In	the	second	step,	the	same	forward	primer	(FR2A	or	
FR3A)	was	used	in	mixtures	with	an	inner	reverse	primer	VLJH.	The	
following	primers	were	used:	FR2A,	TGGRTCCGMCAGSCYYCNGG;	
FR3A,	ACACGGCYSTGTATTACTGT;	LJH,	TGAGGAGACGGTGACC;	
VLJH,	GTGACCAGGGTNCCTTGGCCCCAG.	In	both	steps,	the	PCR	
mixture	contained	TaKaRa	Taq	reagents	(Takara,	Shiga,	Japan).	The	
first	 PCR	 (35	 cycles)	 contained	 100	ng	DNA	 and	 the	 second	 PCR	
(20	cycles)	contained	1	μL	of	 the	undiluted	first	PCR	product.	The	
standard	 PCR	 cycle	 condition	 of	 the	 first	 step	 consisted	 of	 dena-
turation	at	94°C	for	15	seconds,	annealing	at	55°C	for	30	seconds,	
and	extension	at	72°C	for	30	seconds.	The	PCR	cycle	of	the	second	
step	consisted	of	denaturation	at	94°C	for	10	seconds,	annealing	at	
55°C	for	10	seconds,	and	extension	at	72°C	for	10	seconds.	These	
reactions	were	preceded	by	an	initial	denaturation	step	at	94°C	for	
5	minutes	and	concluded	by	a	final	extension	at	72°C	for	7	minutes.	
PCR	products	(10	μL)	were	analyzed	on	3%	agarose	gel	stained	with	
ethidium	bromide	by	electrophoresis	and	viewed	under	ultraviolet	
light.	 Additionally,	 to	 improve	 resolution,	 PCR	 products	were	 also	
run	on	acrylamide	gel.
PCR	amplicons	were	extracted	by	using	QIAquick	Gel	Extraction	
Kit	(Qiagen,	Hilden,	Germany)	and	sequenced	by	direct	sequencing.	
Obtained	sequences	were	analyzed	using	IMGT/V-	QUEST	from	the	
international	 ImMunoGeneTics	 information	system	 (IMGT)	 (http://
www.imgt.org).10
3  | RESULTS
3.1 | Clinical features and quality evaluation of 
tumor samples
Clinical	and	histological	 findings	of	five	PCNSL	patients	who	experi-
enced	extra-	CNS	relapse	are	summarized	in	Tables	S4	and	S5.	In	all	five	
patients,	first	complete	response	(CR)	was	achieved	during	or	at	the	end	
of	the	modified	European	Organisation	for	Research	and	Treatment	of	
Cancer	 (EOTRC)	 chemotherapy	 for	PCNSL4	 and	was	maintained	 for	
more	than	1	year	(Figure	S1).	Subsequently,	extra-	CNS	relapse	occurred	
(Figure	S1).	Median	time	from	diagnosis	of	PCNSL	to	extra-	CNS	relapse	
was	18	months	(Table	S4).	Sites	of	extra-	CNS	relapse	were	maxillary	
sinus	and	submandibular	 lymph	nodes	in	patient	T1,	 intra-	abdominal	
lymph	nodes	and	subcutaneous	tissue	of	back	in	T2,	subcutaneous	tis-
sue	of	right	thigh	in	T5,	left	breast,	and	left	supraclavicular	and	intra-	
abdominal	lymph	nodes	in	TP39,	and	subcutaneous	tissue	of	lower	back	
     |  403HATTORI eT Al.
and	submandibular	 lymph	nodes	in	TP44	(Table	S4).	All	five	patients	
had	no	detectable	lesions	in	the	CNS	at	the	time	of	diagnosis	of	extra-	
CNS	relapse.	However,	in	one	patient	(patient	T1),	magnetic	resonance	
imaging	(MRI)	findings	confirmed	CNS	relapse	in	the	left	frontal	lobe	
and	the	left	optic	nerve	1	month	after	diagnosis	of	extra-	CNS	relapse	 
(Figure	S1).	Tumor	cell	content	of	each	primary	intra-	CNS	and	relapsed	
extra-	CNS	tumor	sample	varied	from	1.09%	to	90%	in	flow	cytometric	or	
histological	analysis	(Table	S6).	Quality	of	the	extracted	DNA	from	tumor	
samples	was	described	as	ΔΔCT	based	on	the	results	of	real-	time	quanti-
tative	PCR	by	using	Agilent	FFPE	QC	Kit	(Agilent,	Wilmington,	USA)	(Data	
S1).	ΔΔCT	of	paired	tumor	samples	varied	from	0.01	to	0.76	(Table	S7).
3.2 | Recurrently mutated genes in PCNSL patients
Targeted	deep	sequencing	was	carried	out	for	39	genes	in	five	tumor	
pairs	 using	 the	 Lymphopanel8	 and	 our	 in-	house	 PCNSL	 panel.4 
Mean	coverages	 in	each	panel	were	1593	×	(range,	370-	3099)	and	
1563	×	(range,	 1084-	1990),	 respectively.	 In	 primary	 intra-	CNS	 tu-
mors,	 61	 probable	 somatic	mutations	were	 identified	 including	 53	
nonsilent	 single	 nucleotide	 variants	 (SNV),	 seven	 deletions,	 and	
one	 insertion.	Recurrent	gene	mutations	were	found	 in	these	such	
as MYD88	 (4/5),	CD79B	 (4/5),	PIM1	 (3/5),	KMT2D	 (3/5),	and	GNA13 
(3/5).	The	mutation	profile	of	intra-	CNS	tumors	in	our	study	was	con-
sistent	with	that	of	PCNSL	in	a	previous	report,	 in	which	the	same	
Lymphopanel	was	used.11	In	relapsed	extra-	CNS	tumors,	68	probable	
somatic	mutations	were	identified	including	57	nonsilent	SNV,	eight	
deletions,	and	three	insertions.	Genes	such	as	MYD88	(4/5),	CD79B 
(3/5),	PIM1	 (4/5),	KMT2D	 (3/5),	 and	PRDM1	 (3/5)	were	 recurrently	
mutated	 (Figure	1;	 Table	 S8).	 An	 aberrant	 somatic	 hypermutation	
(aSHM)	indicator	value	was	calculated	according	to	the	algorithm	of	
Khodabakhshi	 et	al.12	 The	 value	was	 lower	 than	 0.1,	 showing	 that	
PIM1	mutations	were	associated	with	aSHM	(Data	S1,	Table	S9).12
3.3 | Landscape of somatic mutations in 
primary intra- and relapsed extra- CNS tumors of 
PCNSL patients
We	found	shared	mutations	 in	all	 five	paired	tumors	and	unique	
mutations	 in	 all	 five	 intra-	CNS	 tumors	 and	 in	 four	 out	 of	 five	
extra-	CNS	 tumors	 (Figure	2).	 In	 total,	 16	mutations	 in	 11	 genes	
were	found	to	be	shared	(Figures	2	and	3;	Table	S8).	MYD88	(4/5)	
mutations,	L265P	 in	 three	and	P258L	 in	one,	were	 the	most	 re-
currently	shared	mutations.	CD79B	(3/5),	KMT2D	(3/5),	and	PIM1 
(2/5)	 mutations	 also	 emerged	 as	 recurrently	 shared	 mutations,	
among	which	Y196	CD79B	 (3/5),	and	Q2951R	KMT2D	 (2/5)	were	
identified	 as	 hotspot	 mutations	 (Figure	1,	 Table	 S8).	 Forty-	five	
mutations	 in	 six	 genes,	 including	 recurrent	GNA13 and CREBBP 
mutations	were	specific	to	primary	 intra-	CNS	tumors.	 (Figures	2	
and	3;	Figure	S2,	Table	S8).	Fifty-	two	mutations	in	six	genes	were	
specific	to	relapsed	extra-	CNS	tumors	(Figures	2	and	3;	Figure	S2,	
Table	S8).
3.4 | Divergent evolution of primary intra- and 
relapsed extra- CNS tumors from a CPC
These	distribution	patterns	of	shared	and	separated	mutations	strongly	
indicated	the	presence	of	CPC	that	precedes	the	development	of	pri-
mary	 intra-	CNS	 tumors.	 To	 seek	 the	 localization	 of	 the	 CPC	 in	 the	 
B-	lineage	cell	differentiation	map,	IgH	rearrangement	status	of	paired	
tumors	was	examined	in	paired	tumors	of	patients	T1,	T5,	and	TP39	
(Figures	4	and	5).	PCR	products	of	the	CDR3	region	of	IgH showed a 
single	sharp	band	the	same	size	in	both	intra-	and	extra-	CNS	tumors	of	
F IGURE  1 Recurrently	mutated	
genes	with	primary	central	nervous	
system	lymphoma	(PCNSL).	Comparison	
of	mutated	genes	between	primary	or	
relapsed	extra-	central	nervous	system	
tumors	of	PCNSL.	Numbers	of	mutations	
are	indicated	when	more	than	one	
mutation	was	detected	in	the	genes
F IGURE  2 Number	of	somatic	variants	in	each	primary	central	
nervous	system	(CNS)	lymphoma	tumor	sample.	Targeted	deep	
sequencing	for	39	genes	was	carried	out	for	five	paired	tumors.	
Number	of	mutations	found	in	both	tumors	(shared	mutations),	
those	specific	to	primary	intra-	CNS	tumors,	and	those	specific	to	
extra-	CNS	tumors	is	indicated
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patient	T1	(Figure	4).	Direct	sequencing	of	the	clonal	bands	confirmed	
that	both	tumors	shared	identical	CDR3	sequences	(Figure	4).	In	con-
trast,	multiple	bands	were	observed	in	the	intra-	CNS	tumors	of	patient	
T5	and	TP39,	whereas	the	extra-	CNS	tumor	of	each	patient	appeared	
to	have	a	single	band	(Figure	5).	CDR3	sequences	of	both	extra-	CNS	
and	 intra-	CNS	 tumors	 of	 patients	 T5	 and	 TP39	 could	 not	 be	 deter-
mined	by	direct	sequencing.	Then,	the	PCR	products	were	cloned	into	
a	plasmid	and	each	clone	recovered	from	Escherichia coli colonies was 
sequenced	to	determine	the	clonality.	Variable	regions	of	IgH	(VH)	were	
derived	from	either	the	VH3	or	VH4	family	in	both	tumors	of	T5	(Table	
F IGURE  3 Overlaps	in	genes	and	somatic	mutations	discovered	in	intra-	and	extra-	central	nervous	system	(CNS)	tumors.	Venn	diagram	
shows	the	comparison	of	genes	and	mutations	between	five	intra-	and	extra-	CNS	tumor	samples	(A)	Mutated	genes	shared	between	intra-	
and	extra-CNS	tumors	were	shown	in	overlap	of	the	venn	diagram.	Detail	of	shared	mutated	genes	were	written	under	“Common	genes”.	
(B)	Somatic	mutations	shared	between	intra-	and	extra-CNS	tumors	were	shown	in	overlap	of	the	venn	diagram.	Detail	of	shared	mutations	
were	written	under	“Common	mutations”.
F IGURE  4  IgH	rearrangement	status	of	paired	tumors	in	patient	T1.	(A)	Photographs	of	PCR	gels	and	(B)	the	electropherogram	of	direct	
sequencing	show	the	IgH	rearrangement	status	of	paired	tumors	in	patient	T1.	CNS,	central	nervous	system
F IGURE  5 PCR	analysis	of	IgH 
rearrangement	status	of	paired	tumors	
in	patients	T5	and	TP39.	Photographs	of	
PCR	gels	show	the	IGH	rearrangement	
status	of	paired	tumors	in	patients	T5	and	
TP39.	CNS,	central	nervous	system
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S10).	Nevertheless,	the	CDR	sequences	were	mostly	mapped	to	the	VH	
genes	of	the	VH3	family	(VH3-	23*04,	V3-	72*01,	or	V3-	30-	3*03)	in	the	
intra-	CNS	tumor,	whereas	VH4-	4*07	of	the	VH4	family	was	dominant	in	
the	extra-	CNS	tumor	(intra-	CNS	tumor,	VH3	16/18	[89%]	vs	VH4 2/18 
[11%];	extra-	CNS	tumor,	VH3	3/17	[18%]	vs	VH4	14/17	[82%])	 (Table	
S10).	In	TP39,	VH	were	derived	from	the	VH4-	4*07	of	the	VH4	family	
in	the	intra-	CNS	tumor,	whereas	VH3-	21*01	of	the	VH3	family	was	de-
tected	in	the	extra-	CNS	tumor	(intra-	CNS	tumor,	VH3	1/17	[6%]	vs	VH4 
16/17	[94%]	extra-	CNS	tumor,	VH3	18/18	[100%]	vs	VH4	0/100	[0%])	
(Table	S10).	Homology	with	the	germline	sequence	and	usage	of	VH-	
DH-	JH	genes	are	summarized	in	Table	S10	and	Figure	S3.	Predominantly	
repeated	or	similar	clones	with	identical	V-	D-	J	usage	were	identified	in	
all	tumor	samples.	In	T5	intra-	CNS	tumor,	clones	with	VH3-	23*01/DH4-	
23*01/JH6*02	rearrangement	and	those	with	VH3-	72*01/DH6-	25*01/
JH6*03	rearrangement	were	 identified	dominantly	 in	4/18	[22%]	and	
4/18	[22%]	(Table	S10).	In	T5	extra-	CNS	tumor,	clones	with	VH4-	4*07/
DH5-	24*01/JH4*01	were	dominantly	identified	in	14/17	[82%],	in	TP39	
intra-	CNS	 tumor,	 those	 with	 VH4-	4*07/DH5-	24*01/JH4*01	 in	 16/17	
[94%]	 and	 in	 TP39	 extra-	CNS	 tumor,	 those	 with	 VH3-	21*01/DH6-	
19*01/JH4*01	 in	15/18	 [83%]	 (Table	S10).	Almost	all	VH	were	highly	
mutated	(T5	intra-	CNS	tumor,	17/18;	T5	extra-	CNS	tumor,	14/17;	TP39	
intra-	CNS	 tumor,	 16/17;	 TP39	 extra-	CNS	 tumor,	 18/18)	 presumably	
because	of	ongoing	hypermutation13–16	(Table	S10,	Figure	S3).
These	analyses	imply	that	the	CPC	is	mapped	at	distinct	positions	
in	 B-	lineage	 differentiation;	 the	 position	 after	 IgH	 rearrangement	
and	even	after	hypermutation	at	the	variable	region	was	suggested	
in	 T1,	whereas	 emergence	 of	 CPC	 before	 IgH	 rearrangement	was	
suggested	in	T5	and	TP39.
3.5 | Detection of L265P MYD88 mutations in 
BMMNC or PBMNC with droplet digital PCR
To	further	characterize	the	initiation	of	PCNSL	that	is	theorized	to	
precede	the	emergence	of	CPC,	we	analyzed	PBMNC	of	T1	collected	
at	 the	 diagnosis	 of	 extra-	CNS	 relapse	 and	BMMNC	of	 T1,	 T2,	 T5	
and	20	PCNSL	patients	in	an	extended	cohort	collected	at	diagnosis	
(N	=	24).	These	24	cases	were	those	in	whom	the	L265P	MYD88 mu-
tations	were	identified	in	primary	PCNSL	tumors.	According	to	the	
pathological	diagnosis,	no	clinical	evidence	of	lymphoma	infiltration	
was	found	 in	the	bone	marrow	(BM)	of	 these	patients.	The	L265P	
MYD88	mutations	were	 identified	 in	PBMNC	 (T1)	 and	 in	nine	out	
of	23	BMMNC	 (in	 total,	10	of	24)	by	droplet	digital	PCR	 (ddPCR),	
whereas	the	mutations	were	not	detected	in	any	of	the	samples	by	
TDS,	a	less	sensitive	method	(Figure	S4,	Table	S11).
4  | DISCUSSION
This	 is	 the	 first	 multidimensional	 study	 of	 mutational	 dynam-
ics	 comparing	mutational	 profiles	 between	 intra-	CNS	 tumors	 and	
extra-	CNS	 tumors.	 In	 our	 study,	 all	 the	 five	 paired	 tumors	 shared	
multiple	mutations.	Unique	somatic	mutations	were	observed	in	all	
the	 five	 intra-	CNS	 tumors	 and	 four	 out	 of	 five	 extra-	CNS	 tumors	
(Table	S8,	Figure	S2).	Among	the	somatic	mutations	specific	to	intra-	
CNS	tumors,	TBL1XR1	mutation	was	reported	to	be	more	prevalent	
in	PCNSL	 than	 in	DLBCL	not	otherwise	 specified	 (NOS).17	 In	 con-
trast,	a	SOCS1	mutation	was	detected	in	the	tumor	of	subcutaneous	
tissue	 in	TP44	(Table	S4).	SOCS1	mutations	are	known	to	be	more	
prevalent	 in	primary	cutaneous	diffuse	 large	B-	cell	 lymphoma,	 leg	
type	compared	 to	DLBCL	NOS.18	 Therefore,	 somatic	mutations	 in	
these	genes	may	bias	the	location	of	tumors.	These	results	suggest	
that	 the	 paired	 tumors	 originate	 from	divergent	 evolution	 of	CPC	
through	accumulation	of	distinct	mutations.
Recent	 studies	 have	 proposed	 that	 primary	 and	 relapsed	 tu-
mors	 in	 several	hematological	 cancers	may	arise	 from	CPC.6,7,18-20 
Previously,	 it	was	 reported	 that	 the	 dominant	 clones	were	 identi-
cal	 in	paired	 tumors	of	primary	and	 relapsed	MCL	and	FL	accord-
ing	 to	 the	VDJ	 coding	 joints,	 suggesting	 that	CPC	may	 arise	 after	
F IGURE  6 Stages	of	divergence	
from	common	precursor	cells	to	
tumors.	Black	arrows	indicate	the	
clonal	pathway	between	samples.	CLL,	
chronic	lymphocytic	leukemia;	CNS,	
central	nervous	system;	FL,	follicular	
lymphoma;	MCL,	mantle	cell	lymphoma;	
PCNSL,	primary	central	nervous	system	
lymphoma
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VDJ	 rearrangement	 (Figure	6).6,7	 In	 contrast,	 in	 a	 part	 of	 Richter	
syndrome,	 distinct	 IgH	 clones	were	 observed	 between	 aggressive	
lymphomas	and	primary	chronic	lymphocytic	leukemia	(CLL)	tumors	
suggesting	 that	 divergence	may	 occur	 before	 the	 VDJ	 rearrange-
ments.19,20	In	the	current	study,	the	existence	of	identical	monoclonal	
B-	cell	clones	in	both	intra-	and	extra-	CNS	tumors	of	T1	suggests	that	
divergence	from	CPC	could	occur	after	the	point	of	IgH	rearrange-
ment,	similar	to	the	case	of	FL	and	MCL	(Figure	6).	In	contrast,	dis-
tinct	IgH	clones	were	observed	in	the	intra-	and	extra-	CNS	tumors	of	
patients	T5	and	TP39,	which	suggests	that	divergence	of	CPC	could	
occur	preceding	a	VDJ	rearrangement	in	BM,	similar	to	the	case	of	
Richter	syndrome	in	CLL	(Figure	6).19,20	In	a	previous	analysis,	tumor-	
related	IgH	clones	were	detected	in	blood	and	bone	marrow	of	three	
PCNSL	patients.21	These	 results	suggest	 that	divergence	 from	the	
CPC	could	occur	after	the	point	of	IgH	rearrangement	in	all	of	these	
patients,	 although	 hypermutations	 occurred	 independently	 in	 IgH 
clones	of	primary	 tumors	 in	 the	CNS	and	 in	 those	 in	 the	systemic	
sites.21	This	pattern	is	similar	to	the	case	of	patient	T1	in	our	study	
in	which	identical	monoclonal	B-	cell	clones	existed	in	both	intra-	and	
extra-	CNS	tumors,	although	independent	hypermutations	were	not	
observed	in	these	tumors.	In	contrast,	the	findings	in	patients	T5	and	
TP39	were	remarkable	because	VDJ	usage	was	different	between	
intra-	and	extra-	CNS	tumors	in	these	two	patients.
It	 has	 been	 suggested	 that,	 in	 FL	 and	MCL,	 the	 initial	 genetic	
events	may	occur	in	pre-	B	stage	of	differentiation	during	the	recom-
bination	 of	 the	VDJ	 segments	 in	 the	BM	because	 the	 tumor	 cells	
harbor IgH	fusions	with	other	genes:	IgH/BCL2	in	FL	and	IgH/CCND1 
in	MCL.	 In	several	types	of	 lymphomas,	the	 initiating	events	could	
be	 tracked	 back	 even	 to	 hematopoietic	 stem/progenitor	 cells	 up-
stream	of	the	lineage	commitment	towards	either	B	cells	or	T	cells:	
NOTCH1 and SF3B1	mutations	in	CLL,22 BRAF	mutations	in	hairy	cell	
leukemia23 and TET2/DNMT3A	 mutations	 in	 angioimmunoblastic	
T-	cell	 lymphomas.24-26	 Frequent	 detection	 of	 L265P	 MYD88 mu-
tation	 in	BM	 suggests	 that,	 in	PCNSL	patients,	 this	mutation	may	
occur	before	or	during	the	B-	cell	differentiation	process	before	the	
cells	leave	the	BM	environment	and	migrate	to	the	peripheral	lym-
phoid	organs	as	naïve	mature	B	lymphocytes.	This	theory,	however,	
needs	further	proof	because	the	presence	of	minimal	contamination	
of	 lymphoma	 cells	 in	 the	BM	was	 not	 completely	 excluded	 in	 our	
study,	 although	 the	 presence	 of	 lymphoma	 cells	was	 excluded	 by	
immunohistochemical	evaluation	and	flow	cytometry.	Additionally,	
we	were	unable	to	examine	the	L265P	MYD88	mutation	in	healthy	
individuals.	The	L265P	MYD88	mutation	was	detected	in	PBMNC	of	
only	one	subject	at	a	mutation	allele	frequency	of	23%	in	a	cohort	
of	12	380	patients	with	psychiatric	disease.27	This	mutation	was	un-
detected	in	that	of	any	subject	in	another	large	cohort	of	17	182	in-
dividuals	without	hematological	malignancies.28	Because	the	cutoff	
levels	of	mutation	allele	frequencies	in	both	studies	were	2%,	smaller	
allele	frequencies	could	have	escaped	detection	and,	therefore,	the	
possibility	cannot	be	completely	excluded	that	very	few	cells	with	
L265P	MYD88	are	present	even	in	healthy	individuals.
In	conclusion,	our	data	suggest	that	intra-	and	extra-	CNS	tumors	
might	originate	from	the	CPC	in	PCNSL.	The	initial	event	could	be	
a	mutation	 in	 the	MYD88	 gene,	 and	 the	emergence	of	CPC	might	
follow	by	acquisition	of	subsequent	genetic	alterations.	Precise	clar-
ification	of	these	steps	may	contribute	to	establishing	more	robust	
biomarkers	and	therapeutic	approaches	with	newly	developed	tar-
geted	drugs.
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